News Bayer buys into KRAS with $1.3bn Kumquat deal Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat.
News Merck partners Remepy in PDURS-focused alliance Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
